Merus N.V. (MRUS) Provides 2023 Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. GOOGL
6. RTX
7. COF
8. SMCI
9. TSLA
10. BRZE

Go back to Merus N.V. (MRUS) Provides 2023 Outlook

Merus Provides 2023 Outlook

January 8, 2023 9:00 AM EST

- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (NRG1+) cancer have been treated with zenocutuzumab (Zeno) monotherapy

- Petosemtamab clinical update planned for first half of 2023

- MCLA-129 clinical update planned for second half of 2023

- Based on the Companys current operating plan, existing cash, cash equivalents and marketable securities, expected to fund Merus operations into second half 2025

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing... More